Amneal Pharmaceuticals Inc [AMRX] stock is trading at $9.45, up 0.64%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AMRX shares have gain 10.66% over the last week, with a monthly amount glided 14.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amneal Pharmaceuticals Inc [NASDAQ: AMRX] stock has seen the most recent analyst activity on June 06, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $12. Previously, JP Morgan upgraded its rating to Overweight on February 24, 2025, and elevated its price target to $12. On September 06, 2024, upgrade upgraded it’s rating to Neutral but maintained its price target of $9 on the stock. Goldman upgraded its rating to a Buy and raised its price target to $6.50 on March 08, 2021. Guggenheim upgraded its rating to Buy for this stock on December 14, 2020, but kept the price target unchanged to $5.50. In a note dated December 14, 2020, Barclays upgraded an Overweight rating on this stock and boosted its target price from $4.50 to $6.
Amneal Pharmaceuticals Inc [AMRX] stock has fluctuated between $6.68 and $9.48 over the past year. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Amneal Pharmaceuticals Inc [NASDAQ: AMRX] shares were valued at $9.45 at the most recent close of the market. An investor can expect a potential return of 16.4% based on the average AMRX price forecast.
Analyzing the AMRX fundamentals
Amneal Pharmaceuticals Inc [NASDAQ:AMRX] reported sales of 2.85B for the trailing twelve months, which represents a growth of 3.24%. Gross Profit Margin for this corporation currently stands at 0.38% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is -0.03 and Total Capital is 0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-22.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.33 points at the first support level, and at 9.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.58, and for the 2nd resistance point, it is at 9.71.
Ratios To Look Out For
For context, Amneal Pharmaceuticals Inc’s Current Ratio is 1.43. As well, the Quick Ratio is 0.88, while the Cash Ratio is 0.07. Considering the valuation of this stock, the price to sales ratio is 1.04 and price to earnings (TTM) ratio is 1476.56.
Transactions by insiders
Recent insider trading involved Shah Nikita, Executive Vice President, that happened on Aug 14 ’25 when 71694.0 shares were sold. Executive Vice President & CFO, Konidaris Tasos completed a deal on Aug 15 ’25 to sell 0.22 million shares. Meanwhile, Executive Vice President & CFO Konidaris Tasos sold 0.16 million shares on Aug 13 ’25.
